Diamyd Logo
This website is only intended for investors

Fighting diabetes

Diamyd Medical is a diabetes company active in the field of pharmaceutical development. The Company is headquartered in Stockholm, Sweden and shares are listed on NASDAQ OMX First North (ticker: DMYD B).
We strongly believe in attacking the disease process from several angles by combining Diamyd® with other drugs.
Diabetes is associated with serious complications due to elevated and fluctuating blood sugar levels, causing substantial suffering and extensive costs for society.
At the beginning of June, the final participants were included in the researcher-initiated study DIABGAD-1 following intensive and successful recruitment efforts. Slightly more than 60 children and...
Diamyd® is a GAD-based therapy under development for the treatment and prevention of autoimmune diabetes such as type 1 diabetes and LADA. Treatment with Diamyd® aims to intervene in the autoimmune...
rss icon